: Quality of life and affective outcomes offer a perspective of the burden of disease experienced by people with substance use disorder. This can be considered an alternative measure of substance use disorder severity. This review aims to evaluate the impact of exercise as a novel intervention on quality of life and affect in substance use disorder. : Medline, CINAHL, Amed, Web of Science core collections, Embase, PsychINFO and SportDISCUS databases were searched from inception to August 2021 for studies that assessed the impact of exercise on mood, depression, anxiety and quality of life outcomes in substance use disorder. Exercise interventions of any duration were included. : Forty-two studies met the inclusion criteria. Quality of life scores improved with larger effects seen in studies with two or more sessions per week. Depression and anxiety scores decreased, with 19 of the 25 data sets reporting a reduction in depression (effect size 0.2-1.86) and 13 of the 17 data sets reporting a reduction in anxiety (effect sizes 0.2-1.42). Mood improved in six of the seven data sets reviewed with effect sizes ranging from 0.34 to 1.13. : Included studies had numerous methodological flaws therefore results need to be interpreted with caution. Further research needs to be completed with more rigorous methodologies to support these results. : Results indicate promising responses to exercise as a novel intervention for quality of life and mood in substance use disorder, however further research of high methodological quality is needed to confirm.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/10826084.2022.2052098 | DOI Listing |
Pulmonary arterial hypertension (PAH) is a chronic progressive exacerbation of cardiopulmonary vascular disease. The patients' exercise endurance decreased progressively and the survival rate was low. Current basic therapy and targeted drug therapy can improve the quality of life (QoL) of PAH patients, but the long-term efficacy and prognosis are not good.
View Article and Find Full Text PDFInt J Integr Care
December 2024
Departamento de Enfermería, Facultad de Enfermería, Fisioterapia y Podología, Universidad de Sevilla, Spain.
Background: Higher life expectancy has produced a higher older people porpulation, not necessarily with a consistent quality of life, showing a high rate of vulnerability and dependence. The current social and health crisis situation has highlighted the need to create new integrated models of care that could be translated into social and health policies.
Objective: The present study aims to develop, test, and validate an innovative integrated care model for older people with dependence and at risk of social exclusion and their caregivers.
Front Oncol
December 2024
Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Objective: To assess the cost-effectiveness of combining camrelizumab with rivoceranib versus sorafenib as initial treatment options for advanced hepatocellular carcinoma (HCC) across different developmental regions in China.
Methods: Utilizing TreeAge Pro and data from the phase III randomized CARES-310 clinical trial, a model based on Markov state transitions was developed. Health state utility values were derived from the CARES-310 trial, and direct medical costs were obtained from relevant literature and local pricing data.
Cureus
December 2024
Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence, ITA.
This post-market clinical follow-up (PMCF) study evaluates the clinical effectiveness and safety of the external radio electric reprogramming for atrial fibrillation (EX-RER AF) protocol, a non-invasive regenerative medicine approach utilizing radio electric asymmetric conveyer (REAC) technology for managing paroxysmal atrial fibrillation (PAF). Administered with the REAC BENE mod 110 device (ASMED, Scandicci, Italy), the treatment involves a standardized procedure, with the asymmetric conveyor probe (ACP) positioned in the precordial area and fixed, unmodifiable parameters ensuring consistency and reproducibility. During a 36-month post-market clinical follow-up (PMCF), 20 patients with prior diagnoses of PAF underwent the protocol.
View Article and Find Full Text PDFGMS J Med Educ
November 2024
Universitätsklinikum Jena, Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Jena, Germany.
Introduction: Integrative oncology combines evidence-based methods of oncological therapy, supportive medicine, nutrition and physical activity as well as complementary medicine and can significantly improve the effectiveness of therapy and the quality of life for cancer patients. However, scientifically based continuing education in this area has so far rarely been available.
Project Outline: The part-time continuing education program in "Integrative Onkologie" at the University of Jena is the first in Germany to offer scientifically based training for various healthcare professions.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!